Science Corporation Acquires Pixium Vision’s Prima Implant Technology: A Step Forward in Brain-Computer Interface for Vision Restoration

Science Corporation, founded by Neuralink co-founder Max Hodak, has recently acquired the IP and related assets of the Pixium Vision Prima implant, a groundbreaking technology that offers a potential solution for individuals suffering from blindness. The Prima System, which acts as a photovoltaic substitute for photoreceptors, has already received FDA breakthrough device designation and provides simultaneous use of central prosthetic and peripheral natural vision. It was specifically designed for patients with atrophic dry age-related macular degeneration (AMD), offering a miniaturized, wireless, subretinal implant paired with a pocket computer and glasses.

With Science stepping in to acquire the Prima implant technology, there is a sense of relief among Pixium leadership as they look towards continuity for their clinical trials program. Outgoing Pixium CEO Lloyd Diamond expressed confidence in Science’s ability to continue the development and commercialization of the Prima System, stating that it now has a home with a team dedicated to helping patients. The acquisition also adds to Science’s already impressive IP portfolio and represents a significant step forward in their mission to develop cutting-edge brain-computer interface (BCI) technology.

Science Corporation is excited about the acquisition and the opportunity it presents for developing BCI technology for vision restoration. Neuralink co-founder Max Hodak expressed his enthusiasm about this new collaboration, stating that he believes it will have a significant impact on the field of vision restoration and the lives of individuals affected by blindness. Both companies are looking forward to further advancing innovative products using different modalities.

The deal was finalized after Pixium went into liquidation but was approved by the Paris Commercial Court. While the terms of the acquisition were not disclosed, both companies are eagerly anticipating its potential impact on BCI technology development in general.

In conclusion, Science Corporation’s acquisition of Pixium Vision’s IP and related assets marks an important milestone in their mission to develop BCI technology for vision restoration. With their impressive IP portfolio and dedicated team focused on helping patients, they are well positioned to advance this field further than ever before.